Table 1 Demographics and clinical characteristics of patients with HCV genotype 1b treated with elbasvir/grazoprevir

From: Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection

	Total population N = 3614
Age, n (%) years
18–65	2203 (61.0)
> 65	1411 (39.0)
Race/ethnicity, n (%)
Black	2199 (60.9)
White	1099 (30.4)
Other	60 (1.7)
Hispanic	104 (2.9)
Unknown	152 (4.2)
Male, n (%)	3516 (97.3)
BMI, kg/m², n (%)^a
< 25	1176 (32.5)
25 to < 30	1323 (36.6)
≥ 30	1086 (30.1)
Unknown	29 (0.8)
Baseline HCV RNA, n (%)
< 800,000 IU/mL	1106 (30.6)
≥ 800,000 IU/mL	2347 (64.9)
Unknown	161 (4.5)
Platelets count, n (%)
< 100,000 cells/µL	133 (3.7)
≥ 100,000 cells/µL	3180 (88.0)
Missing	301 (8.3)
HCV treatment history, n (%)
Treatment naive	3245 (89.8)
Treatment experienced^b	369 (10.2)
Treatment regimens, n (%)	N = 3584
EBR/GZR for 12 weeks	3201 (89.3)
Treatment-naive	2883 (80.4)
Treatment-experienced	318 (8.9)
EBR/GZR for 8 weeks	240 (6.7)
Treatment-naive	218 (6.1)
Treatment-experienced	22 (0.6)
EBR/GZR + RBV (8–16 weeks)	62 (1.7)
Other	81 (2.3)

BMI body mass index, EBR/GZR elbasvir/grazoprevir, HCV hepatitis C virus
^aChi-square p < 0.05
^bHCV treatment experience was defined as prior use of any interferon-based regimen (with or without ribavirin), the first-generation protease inhibitors boceprevir or telaprevir, or simeprevir or sofosbuvir

Back to article page